Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Price Is Right But Growth Is Lacking After Shares Rocket 36%
As of August 9, 2024, the total number of shareholders for Guangdong Hybribio Biotech (300639.SZ) is 34,097.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on August 13th that as of August 9th, 2024, the total number of shareholders in the company was 34,097.
Guangdong Hybribio Biotech (300639.SZ): Its medical laboratory has the ability to test for monkeypox virus.
On August 13th, Guandong Hybribio Biotech (300639.SZ) stated on its investor relations platform that the company's medical laboratory has the ability to test for monkeypox virus. The company has independently developed a Monkeypox Virus Real-time PCR Kit (fluorescence PCR method) and has obtained CE certification. However, the product has not yet obtained a domestic medical instrument registration certificate. The invention patents related to monkeypox virus include "A kind of monkeypox virus pseudovirus particle and its preparation method" and "A method for simultaneously detecting and identifying monkeypox virus type I, ..."
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Guangdong Hybribio Biotech (300639.SZ): has repurchased 0.39% of its shares.
Guangdong Hybribio Biotech (300639.SZ) announced on July 31 that as of July 31, 2024, the company has cumulatively repurchased 2,505,100 shares, accounting for 0.39% of the current total share capital of the company (excluding the shares in the company's repurchase special securities account); the highest fill price for repurchase is RMB 4.81/share, and the lowest fill price is RMB 4.37/share; the total amount of funds paid is RMB 11,347,431.03 yuan (including transaction costs). This share repurchase program complies with relevant laws and regulations and the company's share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): In July, the company and its subsidiaries received a total of 3 authorized invention patents.
On July 31st, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ), along with its subsidiaries, obtained a total of three authorized invention patents in July 2024. The patents include a microfluidic chip for live cell sorting, a primer and probe combination for detecting 16 pathogenic mutations of the SLC22A5 gene, and a set of primers and reagents based on nucleic acid mass spectrometry for simultaneous detection of folate and nutrient metabolism gene SNP sites in a single tube.
Guangdong Hybribio Biotech (300639.SZ): Its subsidiary third-party medical laboratory has relevant testing technology reserves and can provide related testing services for the disease.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 18 that its third-party medical laboratory has the relevant testing technology reserve and can provide related testing services for the disease.
Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments
Guangdong Hybribio Biotech (300639.SZ): As of June 28th, the total number of shareholders in the company was 33,841.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 8th that as of June 28, 2024, the total number of company shareholders is 33,841.
Guangdong Hybribio Biotech (300639.SZ): Repurchased 0.10% of shares in total.
Guangdong Hybribio Biotech (300639.SZ) announced that as of June 30, 2024, the company has repurchased 655,200 shares, accounting for 0.10% of the company's current total share capital (excluding shares in the company's repurchase special securities account). The highest fill price for repurchases was RMB 4.63/share, and the lowest fill price was RMB 4.58/share. The total amount paid was RMB 3,020,811.82 (including transaction costs). This repurchase of shares complies with relevant laws, regulations, and the company's share buyback program.
Guangdong Hybribio Biotech (300639.SZ): The first buyback of 655,200 shares involves 3.0204 million yuan.
On June 28th, Guangdong Hybribio Biotech (stock code 300639.SZ) announced that on June 28th, 2024, the company repurchased its own shares for the first time through centralized bidding trading using the share buyback special securities account. The repurchased quantity was 655,200 shares, accounting for 0.10% of the company's current total share capital (excluding the shares in the company's share buyback special securities account); the highest fill price for the repurchase was RMB 4.58/share, and the lowest fill price was RMB 4.63/share. The total amount of funds paid was RMB 3,020,359.18 (excluding transaction fees).
Guangdong Hybribio Biotech (300639.SZ): plans to spend 30-60 million yuan to repurchase shares.
Guangdong Hybribio Biotech (300639.SZ) announced on June 27th that the company plans to repurchase some of its shares through centralized bidding with its own funds. The company plans to use its own funds of no less than RMB 30 million (inclusive) and no more than RMB 60 million (inclusive) for the repurchase. The repurchase price of shares shall not exceed RMB 7.20 per share (inclusive). The deadline for the implementation of the share repurchase shall not exceed 3 months from the date when the board of directors approves this share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): Currently there are no other risk warning triggers.
On June 11th, Gelunhui reported that Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform that there is currently no situation triggering other risk warnings according to relevant regulations of the Shenzhen Stock Exchange. In the first quarter of 2024, due to large expenditures related to artificial welfare, depreciation and amortization, leasing, and other expenses in the medical laboratory business, the company's laboratory inspection business sector incurred an overall loss, resulting in a loss in the company's consolidated financial statements. To reverse this situation, the company continues to carry out cost reduction and efficiency improvement work, on one hand, increasing market expansion efforts to improve market share, and on the other hand, strengthening internal management, reducing expenses, and improving laboratory efficiency.
Guangdong Hybrid Bio-tech (300639.SZ): The company and its subsidiaries have been granted a patent for an invention.
On June 11, Gelunhui reported that Guangdong Hybribio Biotech (300639.SZ) and its wholly-owned subsidiary Guangdong Hybribio Technology Creation Co., Ltd. (referred to as "Hybribio Technology Creation") received the notification of granting invention patent rights from the State Intellectual Property Office for the invention and creation of a nucleic acid PCR amplification hybrid reaction instrument and amplification hybrid all-in-one machine. This invention involves the fields of molecular biology technology and nucleic acid amplification hybrid equipment technology, and provides a nucleic acid PCR amplification hybrid reaction instrument and amplification hybrid all-in-one machine. The nucleic acid PCR amplification hybrid reaction instrument includes: chassis, casing, cover and reaction module.
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China
Capbio (300639.SZ) plans to pay 0.65 yuan for 10 shares to be deducted from interest on May 23
CapBio (300639.SZ) announced that the company's 2023 dividend payment plan: for every 10 shares to all shareholders...
Capbio (300639.SZ): The repurchase was completed and the total cost was 30.108 million yuan to repurchase 4.445 million shares
Gelonghui, May 7, 丨 Capcom Biotech (300639.SZ) announced that as of the announcement disclosure date, the share repurchase plan had been implemented. The actual repurchase period was from February 6, 2024 to February 21, 2024. The cumulative number of shares repurchased was 4.445 million shares, accounting for 0.69% of the company's total share capital. The maximum transaction price was RMB 7.42 yuan/share, and the minimum transaction price was RMB 5.84 yuan/share. The total transaction amount was RMB 30.108 million (including transaction fees).
Capbio (300639.SZ): Net loss of 14.354,800 yuan in the first quarter
On April 26, Ge Longhui (300639.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 183 million yuan, a year-on-year decrease of 39.39%; net profit attributable to shareholders of listed companies - 14.3548 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 15.953 million yuan; basic earnings per share - 0.02 yuan.
Capbio (300639.SZ): 2023 net profit of 140 million yuan, plans to distribute 10 to 0.65 yuan
On April 23, Ge Longhui (300639.SZ) announced its 2023 annual report. Operating revenue for the reporting period was 1.04 billion yuan, down 80.27% year on year; net profit attributable to shareholders of listed companies was 140 million yuan, down 91.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 113 million yuan, down 93.47% year on year; it plans to distribute a cash dividend of 0.65 yuan (tax included) for every 10 shares to all shareholders.
Capbio (300639.SZ): No nuclear radiation-related tests on humans or saltwater fish and shrimp
Gelonghui, April 8, 丨 Kepu Biotech (300639.SZ) said on the investor interactive platform that the company is a leading integrated provider of molecular diagnostic products and services. It independently develops, produces and sells a series of testing products and related molecular diagnostic instruments in the field of infectious and hereditary diseases, including tumor testing, maternal and child health, birth defects, infectious diseases, individualized medication, etc. Related products are widely used in hospital clinical diagnosis, large-scale seawater population screening, public health prevention and control. There is no testing related to human or fish nuclear radiation.
No Data